Category: news

January 31, 2017 Off

FDA grants ODD to GenSight’s retinitis pigmentosa drug

By Dino Mustafić

GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa.